Association between triglyceride-glucose index upon admission and the subsequent occurrence of acute kidney injury in adult patients with diabetic ketoacidosis: a single-center retrospective cohort study

入院时甘油三酯-葡萄糖指数与成人糖尿病酮症酸中毒患者随后发生急性肾损伤的相关性:一项单中心回顾性队列研究

阅读:1

Abstract

OBJECTIVE: To explore the association between the triglyceride-glucose (TyG) index at admission and subsequent acute kidney injury (AKI) in adult patients with diabetic ketoacidosis (DKA), and to examine whether a data-driven threshold could aid early risk stratification. METHODS: We conducted a single-centre retrospective cohort study of adults admitted with DKA. Clinical and laboratory variables were extracted and curated from electronic medical records. The TyG index was derived from routine triglyceride and glucose measurements obtained at admission. AKI during hospitalization was defined by KDIGO creatinine criteria. We modelled TyG using restricted cubic splines and in quartiles; multivariable logistic regression adjusted for prespecified confounders. Subgroup analyses evaluated effect modification by sex, age, BMI, diabetes type, and hypertension. RESULTS: A total of 678 adults with DKA were included; 196 (28.9%) developed AKI. The TyG-AKI relationship was non-linear, with risk rising steeply once TyG exceeded 10.92 (Q4). In fully adjusted models, Q4 vs Q1 was associated with higher odds of AKI (OR 2.478, 95% CI 1.285-4.780; p = 0.007). No significant interactions were detected across prespecified subgroups. In sensitivity analyses, findings were directionally consistent. The association was observed across strata without evidence of effect modification. CONCLUSIONS: We observed a non-linear association between admission TyG and subsequent AKI in adults with DKA, with an inflection around TyG ≈ 10.92. These results may help identify patients who warrant closer renal surveillance, yet they should be regarded as exploratory and hypothesis-generating given the single-centre, retrospective design; causality cannot be inferred, and prospective multicentre validation is required before routine clinical adoption.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。